StoxEmcure Pharmaceuticals vs Acutaas Chemicals: share price & financials comparison
NSE: EMCURE vs ACUTAAS · Healthcare · as of 13 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Emcure Pharmaceuticals vs Acutaas Chemicals at a glance
Emcure Pharmaceuticals (EMCURE) has a market capitalisation of ₹44,804 Cr, against ₹33,069 Cr for Acutaas Chemicals (ACUTAAS). Over the past year Acutaas Chemicals has returned +120.2%, compared with +78.3% for Emcure Pharmaceuticals. On valuation, Emcure Pharmaceuticals trades at a lower P/E of 41.0 versus 75.3. Acutaas Chemicals earns a higher return on equity (23.6% vs 20.5%). Emcure Pharmaceuticals comes out ahead on size and valuation. Acutaas Chemicals comes out ahead on profitability, growth, financial health, momentum and technicals. Across the scored metrics below, Emcure Pharmaceuticals leads on 4 and Acutaas Chemicals on 9. On StoxGud's 10-point checklist, Emcure Pharmaceuticals scores 9/10 and Acutaas Chemicals scores 8/10.
| Metric | Emcure Pharmaceuticals | Acutaas Chemicals |
|---|---|---|
| Size | ||
| Market cap | ₹44,804 Cr | ₹33,069 Cr |
| Revenue (latest FY) | ₹9,204 Cr | ₹1,339 Cr |
| Net profit (latest FY) | ₹924 Cr | ₹356 Cr |
| Valuation | ||
| P/E | 41.0 | 75.3 |
| P/B | 8.38 | 17.80 |
| Dividend yield | 0.13% | 0.04% |
| Profitability | ||
| Return on equity | 20.5% | 23.6% |
| Net profit margin | 10.7% | 27.6% |
| Operating margin | 20.4% | 39.1% |
| Growth | ||
| Revenue growth (YoY) | +24.3% | +42.7% |
| Net profit growth (YoY) | +33.7% | +73.3% |
| Revenue CAGR (multi-year) | — | +26.7% |
| Financial health | ||
| Debt to equity | 0.27 | 0.00 |
| Momentum | ||
| 1-month return | +26.4% | +27.1% |
| 1-year return | +78.3% | +120.2% |
| 3-year CAGR | — | +95.5% |
| 5-year CAGR | — | +52.3% |
| Distance from 52W high | +0.0% | +0.0% |
| Technicals | ||
| RSI (14) | 94 | 79 |
| Price vs 200-day avg | +34.8% | +38.5% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Emcure Pharmaceuticals | Acutaas Chemicals |
|---|---|---|
| Price above 50-day average | ✓ | ✓ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✗ | ✗ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✓ | ✓ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✓ | ✓ |
| P/E below industry median | ✓ | ✗ |
| Score | 9/10 | 8/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Emcure Pharmaceuticals or Acutaas Chemicals?
Emcure Pharmaceuticals has a market cap of ₹44,804 Cr and Acutaas Chemicals has a market cap of ₹33,069 Cr as of 13 Nov 2026.
Which has a lower P/E, Emcure Pharmaceuticals or Acutaas Chemicals?
Emcure Pharmaceuticals has the lower P/E: Emcure Pharmaceuticals trades at 41.0 and Acutaas Chemicals at 75.3.
Which gave better returns in the last year, Emcure Pharmaceuticals or Acutaas Chemicals?
Acutaas Chemicals did better: Emcure Pharmaceuticals returned +78.3% and Acutaas Chemicals returned +120.2% over one year.
What is the difference between Emcure Pharmaceuticals and Acutaas Chemicals?
Both are NSE-listed companies in Healthcare. Emcure Pharmaceuticals is about 1.4 times the size of Acutaas Chemicals by market cap. In the latest financial year Emcure Pharmaceuticals reported revenue of ₹9,204 Cr and Acutaas Chemicals ₹1,339 Cr. Operating margin is 20.4% for Emcure Pharmaceuticals and 39.1% for Acutaas Chemicals. Debt to equity is 0.27 for Emcure Pharmaceuticals and 0.00 for Acutaas Chemicals.
Which is better, Emcure Pharmaceuticals or Acutaas Chemicals?
It depends on what you are looking for, and StoxGud does not recommend either stock. On the metrics compared above, Emcure Pharmaceuticals leads on 4 and Acutaas Chemicals on 9. Emcure Pharmaceuticals is ahead on size and valuation. Acutaas Chemicals is ahead on profitability, growth, financial health, momentum and technicals. On StoxGud's rules-based checklist Emcure Pharmaceuticals scores 9/10 and Acutaas Chemicals scores 8/10. This is information, not advice: consult a SEBI-registered adviser before investing.